Peter J. Rossi

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial

Ashesh B. Jani, Eduard Schreibmann, Subir Goyal et al. · The Lancet · 2021 · 183 citations · Full text

Medicine, Nuclear Medicine, Oncology +16

Detection of Recurrent Prostate Carcinoma with<i>anti</i>-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

David M. Schuster, Bital Savir-Baruch, Peter T. Nieh et al. · Radiology · 2011 · 149 citations

Medicine, Nuclear Medicine, Radiology +17

Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT

Oluwaseun Odewole, Funmilayo Tade, Peter T. Nieh et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 148 citations

Medicine, Nuclear Medicine, Radiology +12

Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V100 superior to D90?

Michael A. Papagikos, Allan F. deGuzman, Peter J. Rossi et al. · Brachytherapy · 2005 · 51 citations

Medicine, Radiation Oncology, Urology +13

Impact of ¹⁸F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial

Ashesh B. Jani, Eduard Schreibmann, Peter J. Rossi et al. · Journal of Nuclear Medicine · 2016 · 40 citations · Full text

Medicine, Nuclear Medicine, Radiation Oncology +17